ECT204 / Eureka Therap, JW (Cayman) Therap - LARVOL DELTA

Preclinical evaluation of GPC3 targeting antibody-TCR T cells in HCC models with tumor rechallenging (AACR 2025) - "ECT204, a GPC3-targeting T cell product developed using the ARTEMIS Cell Receptor Platform, incorporates an Antibody T-Cell Receptor (AbTCR) combining an antibody-derived targeting domain with a human γδ T-cell receptor effector domain and a Costimulatory Receptor (CSR)1...Cell Discovery. 4, 62 (2018)."

IO biomarker • Late-breaking abstract • Preclinical • B Cell Lymphoma • Hematological Malignancies • Hepatocellular Cancer • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • GPC3 • PD-1

ARYA3: T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Eureka Therapeutics Inc. | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Dec 2026 ➔ Dec 2027

Trial completion date • Trial primary completion date • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor • GPC3

ARYA3: T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Eureka Therapeutics Inc. | Trial completion date: Dec 2027 ➔ Dec 2026

Metastases • Trial completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor • GPC3

ARYA3: T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Eureka Therapeutics Inc. | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Metastases • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor • GPC3

Eureka Therapeutics Advances ARYA-3 Clinical Trial to Phase II for Treatment of Liver Cancer Using GPC3-Targeting ARTEMIS T-cell Therapy (Businesswire) - "Eureka Therapeutics, Inc...announced the advancement of its ARYA-3 clinical trial to Phase II (NCT04864054). This milestone represents one of the first engineered T-cell programs targeting solid tumors to reach Phase II."

Trial status • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

ARYA3: T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Eureka Therapeutics Inc. | Phase classification: P1/2 ➔ P2

Metastases • Phase classification • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor • GPC3

A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Shanghai Ming Ju Biotechnology Co., Ltd.

CAR T-Cell Therapy • Metastases • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor

ARYA3: ECT204 T-Cell Therapy in Adults With Advanced HCC (clinicaltrials.gov) - P1/2 | N=24 | Recruiting | Sponsor: Eureka Therapeutics Inc. | Trial completion date: Jul 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2024 | N=12 ➔ 24

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor • GPC3

GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Shanghai Ming Ju Biotechnology Co., Ltd.

New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor

JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma (PRNewswire) - "JW Therapeutics...announced the initiation of phase I clinical study of JWATM204 in patients with advanced hepatocellular carcinoma (HCC)....This first-in-human study of JWATM204 aims to evaluate the safety, tolerability, dose limited toxicity and pharmacokinetic profile of JWATM204 in adult subjects with advanced HCC, and also to explore the anti-tumor activity of JWATM204 in the target population."

New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Eureka Therapeutics and City of Hope treat first patient with GPC3 targeting ARTEMIS T cells (ECT204) for advanced liver cancer (Eurekalert) - "'City of Hope is committed to finding innovative treatments for challenging solid tumors that currently do not have effective medical treatments,' said Daneng Li, M.D...'Targeting GPC3 with T cell immunotherapy would be a promising approach to treating advanced liver cancer.'"

Media quote

Eureka Therapeutics and City of Hope Treat First Patient with GPC3 Targeting ARTEMIS T Cells (ECT204) for Advanced Liver Cancer (Businesswire) - "Eureka Therapeutics Inc...announced that City of Hope treated the first patient with GPC3-positive advanced hepatocellular carcinoma (HCC), the predominant type of liver cancer, with ECT204, an experimental T cell therapy....'I look forward to treating more patients with this experimental therapy and seeing data from the study to understand the potential of ECT204'."

Trial status • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatocellular Carcinoma (HCC) With ARTEMIS T Cells (Businesswire) - "Eureka Therapeutics...announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ET140203 and ECT204 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. Eureka is currently recruiting patients in three Phase I/II clinical trials to investigate the safety and potential efficacy of ARTEMIS® T cells that have been engineered to target specific liver cancer antigens."

Orphan drug • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

ARYA3: ECT204 T-Cell Therapy in Adults With Advanced HCC (clinicaltrials.gov) - P1/2; N=12; Recruiting; Sponsor: Eureka Therapeutics Inc.; Initiation date: Aug 2021 ➔ Dec 2021

Clinical • Trial initiation date • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor • GPC3

ARYA3: ECT204 T-Cell Therapy in Adults With Advanced HCC (clinicaltrials.gov) - P1/2; N=12; Recruiting; Sponsor: Eureka Therapeutics Inc.; Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor • GPC3

Eureka Therapeutics Announces Initiation of Phase I/II ARYA-3 Clinical Trial of GPC3 Targeting ARTEMIS T Cell Therapy in Liver Cancer (Businesswire) - “Eureka Therapeutics, Inc…announced the initiation of a Phase I/II clinical trial of ECT204, a GPC3 targeting ARTEMIS® T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer. The Phase I portion of the ARYA-3 study is now open for enrollment....'We are excited to provide City of Hope patients with both GPC3 and AFP targeted therapy options to treat HCC,' said Dr. Daneng Li...'Engineered T-cell therapy is a novel approach, and it has the potential to transform how solid tumors will be treated in the future.'"

Enrollment open • Media quote • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology